(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
A phase 2 trial of (Z)-endoxifen in HR-positive / HER2-negative breast cancer, run by Atossa Therapeutics, Inc., active and no longer recruiting.
Overview
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer is a phase 2 interventional study registered as NCT05607004 by Atossa Therapeutics, Inc., with 87 participants enrolled, started 2023-02-14 and due to reach its primary completion in 2026-11. Interventions recorded: (Z)-endoxifen and goserelin.
Similar pages
not linked directly; found by shared links- TrialStudy of TYK-00540 Tablets in Patients With Advanced Solid Tumors
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialComparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialDNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialEfficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.